Influence of Anesthetic Temperature on Cephalad Sensory Blockade With Spinal Anesthesia (ATOCEB)
Recruitment status was Recruiting
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
Several factors influence the extension of anesthetic mixture during spinal anesthesia including anesthetic gravity, body position, drug volume, and drug-delivering velocity. However, the effect of temperature of anesthetic mixture on the cephalad sensory blockade is hitherto unknown. The investigators hypothesized that different temperatures of the anesthetic mixture had different velocity of extension after spinal anesthesia. In addition, previous studies suggest that parturients have relative higher sensitivity to temperature. Herein the investigators proposed that the temperature of anesthetic mixture had more extensive effect on the cephalad sensory blockade with spinal anesthesia for cesarean delivery.
| Condition | Intervention |
|---|---|
|
Cesarean Delivery |
Drug: bupivacaine/fentanyl/morphine |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Endpoint Classification: Safety/Efficacy Study Intervention Model: Parallel Assignment Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor) Primary Purpose: Treatment |
| Official Title: | Influence of Anesthetic Temperature on Cephalad Sensory Blockade With Spinal Anesthesia for Cesarean Delivery |
- Maximum cephalad sensory blockade to pinprick, cold and touch [ Time Frame: From the delivery of anesthetic mixture to 15 min immediate after spinal anesthesia ] [ Designated as safety issue: Yes ]
- Velocity of the sensory blockade at identical body position [ Time Frame: From the delivery of anesthetic mixture to 15 min immediate after spinal anesthesia ] [ Designated as safety issue: Yes ]
- The total dose of phenylephrine required to maintain baseline arterial blood pressure [ Time Frame: From the delivery of anesthetic mixture to 25 min after spinal anesthesia ] [ Designated as safety issue: Yes ]
- Time interval of the occurrence of the hypotension [ Time Frame: From the delivery of the anesthetic mixture to 25 min after spinal anesthesia ] [ Designated as safety issue: Yes ]
| Estimated Enrollment: | 300 |
| Study Start Date: | December 2008 |
| Estimated Study Completion Date: | August 2011 |
| Estimated Primary Completion Date: | August 2011 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
|
Active Comparator: 1
Mixture of anesthetic including hyperbaric bupivacaine 12 mg, fentanyl 10 microg and morphine 200 microg, with the temperature of 20 degree celsius
|
Drug: bupivacaine/fentanyl/morphine
Hyperbaric bupivacaine 12 mg, fentanyl 10 microg and morphine 200 microg
|
|
Experimental: 2
Mixture of anesthetic including hyperbaric bupivacaine 12 mg, fentanyl 10 microg and morphine 200 microg, with the temperature of 10 degree celsius
|
Drug: bupivacaine/fentanyl/morphine
Hyperbaric bupivacaine 12 mg, fentanyl 10 microg and morphine 200 microg
|
|
Experimental: 3
Mixture of anesthetic including hyperbaric bupivacaine 12 mg, fentanyl 10 microg and morphine 200 microg, with the temperature of 15 degree celsius
|
Drug: bupivacaine/fentanyl/morphine
Hyperbaric bupivacaine 12 mg, fentanyl 10 microg and morphine 200 microg
|
|
Experimental: 4
Mixture of anesthetic including hyperbaric bupivacaine 12 mg, fentanyl 10 microg and morphine 200 microg, with the temperature of 25 degree celsius
|
Drug: bupivacaine/fentanyl/morphine
Hyperbaric bupivacaine 12 mg, fentanyl 10 microg and morphine 200 microg
|
|
Experimental: 5
Mixture of anesthetic including hyperbaric bupivacaine 12 mg, fentanyl 10 microg and morphine 200 microg, with the temperature of 30 degree celsius
|
Drug: bupivacaine/fentanyl/morphine
Hyperbaric bupivacaine 12 mg, fentanyl 10 microg and morphine 200 microg
|
|
Experimental: 6
Mixture of anesthetic including hyperbaric bupivacaine 12 mg, fentanyl 10 microg and morphine 200 microg, with the temperature of 35 degree celsius
|
Drug: bupivacaine/fentanyl/morphine
Hyperbaric bupivacaine 12 mg, fentanyl 10 microg and morphine 200 microg
|
Eligibility| Ages Eligible for Study: | 19 Years to 45 Years |
| Genders Eligible for Study: | Female |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Nulliparous women
- > 18 years and < 45 years
Exclusion Criteria:
- Allergy to opioids, a history of the use of centrally-acting drugs of any sort, chronic pain and psychiatric diseases records
- Participants younger than 18 years or older than 45 years
- Those who were not willing to or could not finish the whole study at any time
- Alcohol addictive or narcotic dependent patients
- Subjects with a nonvertex presentation
- Diagnosed diabetes mellitus and pregnancy-induced hypertension
- Twin gestation and breech presentation
- Pregnant fever
Contacts and Locations| Contact: FuZhou Wang, MD | 86-25-84460777 ext 3301 | zfwang50@gmail.com |
| Contact: ShiQin Xu, MD | 86-25-84460777 ext 3301 | xusqnj@sina.com |
| China, Jiangsu | |
| Nanjing Maternal and Child Health Care Hospital | Recruiting |
| Nanjing, Jiangsu, China, 210004 | |
| Contact: YuZhu Peng, MD 86-25-8446-0777 ext 1508 pyz1131@hotmail.com | |
| Contact: XiRong Guo, MD 86-25-8446-0777 ext 1508 xrguonjmueducn@yahoo.com.cn | |
| Sub-Investigator: YuSheng Liu, MD | |
| Study Director: | XiaoFeng Shen, MD | Nanjing Medical University |
More Information
No publications provided
| Responsible Party: | XiaoFeng Shen, Nanjing Medical University |
| ClinicalTrials.gov Identifier: | NCT00815022 History of Changes |
| Other Study ID Numbers: | NMU-200812-MZ32, NJFY0812009 |
| Study First Received: | December 26, 2008 |
| Last Updated: | May 10, 2011 |
| Health Authority: | China: Ethics Committee |
Keywords provided by Nanjing Medical University:
|
Temperature Spinal anesthesia Cesarean section Cephalad sensory blockade Regional anesthesia |
Additional relevant MeSH terms:
|
Anesthetics Bupivacaine Fentanyl Morphine Central Nervous System Depressants Physiological Effects of Drugs Pharmacologic Actions Central Nervous System Agents Therapeutic Uses |
Anesthetics, Local Sensory System Agents Peripheral Nervous System Agents Adjuvants, Anesthesia Narcotics Analgesics Anesthetics, Intravenous Anesthetics, General Analgesics, Opioid |
ClinicalTrials.gov processed this record on May 16, 2013